Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.37 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168310 | 0.94 | VSIR (0.48) | FOLH1VSIRCD274CPB2C3AR1 | |
| SCHEMBL18078190 | 0.92 | VSIR (0.48) | FOLH1VSIRCD274CPB2 | |
| SCHEMBL18078233 | 0.91 | FOLH1 (0.49) | FOLH1VSIRCD274CPB2 | |
| SCHEMBL22676656 | 0.89 | FOLH1 (0.48) | FOLH1VSIRCD274CPB2SLC6A5 | |
| SCHEMBL21168358 | 0.86 | VSIR (0.43) | FOLH1VSIRCD274C3AR1 | |
| SCHEMBL24595340 | 0.85 | VSIR (0.46) | FOLH1VSIRCD274 | |
| SCHEMBL25477029 | 0.85 | VSIR (0.50) | FOLH1VSIRCD274SLC6A5 | |
| SCHEMBL18078181 | 0.85 | FOLH1 (0.49) | FOLH1VSIRCD274CPB2 | |
| SCHEMBL18078185 | 0.85 | VSIR (0.64) | FOLH1VSIRCD274CPB2C3AR1 | |
| SCHEMBL21168316 | 0.84 | FOLH1 (0.47) | FOLH1VSIRCD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-04-26 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2020-05-14 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311517-B2 | Combination of small molecule CD-47 inhibitors with other anti-cancer agents | CD47, CD63, CD99 | FOLH1 1153/4885VSIR 2447/4885CD274 20/4885 |
| US-20200147054-A1 | Combination of Small Molecule CD-47 Inhibitors with Other Anti-Cancer Agents | CD47, CD63, CD99 | FOLH1 1153/4885VSIR 2447/4885CD274 20/4885 |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3099/4885VSIR 2881/4885CD274 345/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3303/4885VSIR 2875/4885CD274 215/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3303/4885VSIR 2875/4885CD274 215/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | FOLH1 3156/4885VSIR 2535/4885CD274 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.